Is KYTX or ZBIO more profitable?

Kyverna Therapeutics' return on equity of -81.92% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.92% -63.74% Zenas BioPharma N/A -122.45% -58.04%

Does the media refer more to KYTX or ZBIO?

In the previous week, Zenas BioPharma had 10 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 12 mentions for Zenas BioPharma and 2 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.63 beat Zenas BioPharma's score of 0.12 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, KYTX or NBTX?

Nanobiotix has higher revenue and earnings than Kyverna Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$2.94 N/A Nanobiotix $29.64M 67.73 -$27.11M N/A N/A

Is KYTX or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.92% -63.74% Nanobiotix N/A N/A N/A

Does the media favor KYTX or NBTX?

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Nanobiotix. MarketBeat recorded 2 mentions for Kyverna Therapeutics and 1 mentions for Nanobiotix. Kyverna Therapeutics' average media sentiment score of 0.63 beat Nanobiotix's score of 0.00 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor STOK or KYTX?

In the previous week, Stoke Therapeutics had 12 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 14 mentions for Stoke Therapeutics and 2 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.63 beat Stoke Therapeutics' score of 0.28 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KYTX or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.92% -63.74% Generate Biomedicines N/A N/A N/A

Does the media favor KYTX or GENB?

In the previous week, Generate Biomedicines had 3 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 5 mentions for Generate Biomedicines and 2 mentions for Kyverna Therapeutics. Generate Biomedicines' average media sentiment score of 0.75 beat Kyverna Therapeutics' score of 0.63 indicating that Generate Biomedicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KYTX or AGIO?

In the previous week, Agios Pharmaceuticals had 10 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 12 mentions for Agios Pharmaceuticals and 2 mentions for Kyverna Therapeutics. Agios Pharmaceuticals' average media sentiment score of 0.65 beat Kyverna Therapeutics' score of 0.63 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kyverna Therapeutics (KYTX) Competitors

$8.24 -0.18 (-2.14%)

Closing price 04:00 PM Eastern

Extended Trading

$8.23 -0.01 (-0.12%)

As of 04:20 PM Eastern

Compare

KYTX vs. ZBIO, NBTX, STOK, GENB, and AGIO

Should you buy Kyverna Therapeutics stock or one of its competitors? Kyverna Therapeutics's main competitors and comparable companies include Zenas BioPharma (ZBIO), Nanobiotix (NBTX), Stoke Therapeutics (STOK), Generate Biomedicines (GENB), and Agios Pharmaceuticals (AGIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kyverna Therapeutics compare to Zenas BioPharma?

Kyverna Therapeutics (NASDAQ:KYTX) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Kyverna Therapeutics has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.03, suggesting that its share price is 203% less volatile than the broader market.

18.1% of Kyverna Therapeutics shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Kyverna Therapeutics has higher earnings, but lower revenue than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A
Zenas BioPharma	$1M	2,062.85	-$377.74M	-$8.99	N/A

In the previous week, Zenas BioPharma had 10 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 12 mentions for Zenas BioPharma and 2 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.63 beat Zenas BioPharma's score of 0.12 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kyverna Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 264.08%. Zenas BioPharma has a consensus target price of $45.71, suggesting a potential upside of 44.44%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Kyverna Therapeutics is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Kyverna Therapeutics' return on equity of -81.92% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.92%	-63.74%
Zenas BioPharma	N/A	-122.45%	-58.04%

Summary

Kyverna Therapeutics beats Zenas BioPharma on 9 of the 14 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Nanobiotix?

Kyverna Therapeutics (NASDAQ:KYTX) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Kyverna Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 264.08%. Nanobiotix has a consensus target price of $37.33, suggesting a potential downside of 5.87%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Kyverna Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Nanobiotix. MarketBeat recorded 2 mentions for Kyverna Therapeutics and 1 mentions for Nanobiotix. Kyverna Therapeutics' average media sentiment score of 0.63 beat Nanobiotix's score of 0.00 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nanobiotix has higher revenue and earnings than Kyverna Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A
Nanobiotix	$29.64M	67.73	-$27.11M	N/A	N/A

Nanobiotix's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.92%	-63.74%
Nanobiotix	N/A	N/A	N/A

Kyverna Therapeutics has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Summary

Kyverna Therapeutics beats Nanobiotix on 6 of the 11 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Kyverna Therapeutics (NASDAQ:KYTX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Stoke Therapeutics has higher revenue and earnings than Kyverna Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$27.59M	75.59	-$6.89M	-$3.34	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

In the previous week, Stoke Therapeutics had 12 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 14 mentions for Stoke Therapeutics and 2 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.63 beat Stoke Therapeutics' score of 0.28 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyverna Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
Kyverna Therapeutics	N/A	-81.92%	-63.74%

18.1% of Kyverna Therapeutics shares are held by institutional investors. 9.6% of Stoke Therapeutics shares are held by insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Stoke Therapeutics currently has a consensus price target of $44.25, suggesting a potential upside of 36.91%. Kyverna Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 264.08%. Given Kyverna Therapeutics' higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Stoke Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market.

Summary

Kyverna Therapeutics beats Stoke Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Generate Biomedicines?

Kyverna Therapeutics (NASDAQ:KYTX) and Generate Biomedicines (NASDAQ:GENB) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Generate Biomedicines' return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.92%	-63.74%
Generate Biomedicines	N/A	N/A	N/A

Kyverna Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 264.08%. Generate Biomedicines has a consensus target price of $25.40, indicating a potential upside of 43.34%. Given Kyverna Therapeutics' higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

18.1% of Kyverna Therapeutics shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Kyverna Therapeutics has higher earnings, but lower revenue than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A
Generate Biomedicines	$31.89M	71.32	-$203.15M	-$1.59	N/A

In the previous week, Generate Biomedicines had 3 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 5 mentions for Generate Biomedicines and 2 mentions for Kyverna Therapeutics. Generate Biomedicines' average media sentiment score of 0.75 beat Kyverna Therapeutics' score of 0.63 indicating that Generate Biomedicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Generate Biomedicines beats Kyverna Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Agios Pharmaceuticals?

Kyverna Therapeutics (NASDAQ:KYTX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Kyverna Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.92%	-63.74%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

18.1% of Kyverna Therapeutics shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Kyverna Therapeutics has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

In the previous week, Agios Pharmaceuticals had 10 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 12 mentions for Agios Pharmaceuticals and 2 mentions for Kyverna Therapeutics. Agios Pharmaceuticals' average media sentiment score of 0.65 beat Kyverna Therapeutics' score of 0.63 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agios Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyverna Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 264.08%. Agios Pharmaceuticals has a consensus price target of $41.25, indicating a potential upside of 26.38%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Kyverna Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40

Kyverna Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A
Agios Pharmaceuticals	$54.03M	36.07	-$412.78M	-$7.01	N/A

Summary

Kyverna Therapeutics beats Agios Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Kyverna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYTX vs. The Competition

Export

Metric	Kyverna Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$509.59M	$3.99B	$7.30B	$12.71B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-2.80	11.76	271.39	24.11
Price / Sales	N/A	1,296.80	604.56	77.78
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	2.14	17.27	11.18	6.40
Net Income	-$161.31M	-$22.72M	$3.46B	$348.28M
7 Day Performance	-7.93%	2.83%	1.97%	0.95%
1 Month Performance	11.20%	9.67%	7.30%	5.15%
1 Year Performance	114.03%	54.74%	24.74%	16.18%

Kyverna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYTX Kyverna Therapeutics	1.9608 of 5 stars	$8.24 -2.1%	$30.00 +264.1%	+118.7%	$509.59M	N/A	N/A	96
ZBIO Zenas BioPharma	2.8548 of 5 stars	$31.91 +4.6%	$45.71 +43.3%	+88.8%	$2.08B	$10M	N/A	N/A
NBTX Nanobiotix	0.8205 of 5 stars	$41.08 -2.3%	$37.33 -9.1%	+331.6%	$2.08B	$29.64M	N/A	100	News Coverage Gap Down
STOK Stoke Therapeutics	2.4266 of 5 stars	$32.14 +0.0%	$43.00 +33.8%	+65.1%	$2.07B	$27.59M	N/A	100	Analyst Forecast
GENB Generate Biomedicines	2.1414 of 5 stars	$16.08 +2.5%	$25.40 +58.0%	N/A	$2.06B	$31.89M	N/A	312	Lockup Expiration Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYTX) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. ZBIO, NBTX, STOK, GENB, and AGIO

How does Kyverna Therapeutics compare to Zenas BioPharma?

Summary

How does Kyverna Therapeutics compare to Nanobiotix?

Summary

How does Kyverna Therapeutics compare to Stoke Therapeutics?

Summary

How does Kyverna Therapeutics compare to Generate Biomedicines?

Summary

How does Kyverna Therapeutics compare to Agios Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. ZBIO, NBTX, STOK, GENB, and AGIO

How does Kyverna Therapeutics compare to Zenas BioPharma?

Which has more risk & volatility, KYTX or ZBIO?

Do insiders & institutionals believe in KYTX or ZBIO?

Which has better earnings & valuation, KYTX or ZBIO?

Does the media refer more to KYTX or ZBIO?

Do analysts prefer KYTX or ZBIO?

Is KYTX or ZBIO more profitable?

Summary

How does Kyverna Therapeutics compare to Nanobiotix?

Do analysts rate KYTX or NBTX?

Does the media favor KYTX or NBTX?

Do insiders and institutionals hold more shares of KYTX or NBTX?

Which has better earnings & valuation, KYTX or NBTX?

Is KYTX or NBTX more profitable?

Which has more risk and volatility, KYTX or NBTX?

Summary

How does Kyverna Therapeutics compare to Stoke Therapeutics?

Which has better valuation and earnings, STOK or KYTX?

Does the media favor STOK or KYTX?

Is STOK or KYTX more profitable?

Do insiders & institutionals hold more shares of STOK or KYTX?

Do analysts recommend STOK or KYTX?

Which has more volatility & risk, STOK or KYTX?

Summary

How does Kyverna Therapeutics compare to Generate Biomedicines?

Is KYTX or GENB more profitable?

Do analysts prefer KYTX or GENB?

Do insiders and institutionals have more ownership in KYTX or GENB?

Which has stronger valuation and earnings, KYTX or GENB?

Does the media favor KYTX or GENB?

Summary

How does Kyverna Therapeutics compare to Agios Pharmaceuticals?

Is KYTX or AGIO more profitable?

Do insiders & institutionals believe in KYTX or AGIO?

Which has more volatility & risk, KYTX or AGIO?

Does the media favor KYTX or AGIO?

Do analysts prefer KYTX or AGIO?

Which has stronger earnings & valuation, KYTX or AGIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools